Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Dow
Mallinckrodt
Express Scripts
Colorcon

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR MIRVASO


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Mirvaso

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02249065 ↗ Mirvaso in Use Study Completed Galderma Laboratories, L.P. Phase 4 2014-09-01 This study is designed to: 1. assess the signs and symptoms of rosacea, including erythema, without treatment and during treatment with Mirvaso® gel 2. further characterize lifestyle impact and patient satisfaction with Mirvaso® treatment 3. gain a better understanding of the real-world use of Mirvaso® on the pattern and management of facial erythema of rosacea.
NCT02289352 ↗ Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea Completed Watson Laboratories, Inc. Phase 3 2014-07-01 A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Therapeutic Equivalence of Brimonidine Topical Gel, 0.33% (Watson Laboratories, Inc., USA) to Reference Product Mirvaso® (brimonidine) topical gel, 0.33% (Galderma Laboratories, L.P., USA) in Patients with Moderate to Severe Facial Erythema Associated with Rosacea
NCT02289352 ↗ Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea Completed Actavis Inc. Phase 3 2014-07-01 A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Therapeutic Equivalence of Brimonidine Topical Gel, 0.33% (Watson Laboratories, Inc., USA) to Reference Product Mirvaso® (brimonidine) topical gel, 0.33% (Galderma Laboratories, L.P., USA) in Patients with Moderate to Severe Facial Erythema Associated with Rosacea
NCT02568111 ↗ Brimonidine Tartrate for the Treatment of Injection Related Erythema Withdrawn Biogen Phase 4 2016-02-01 The primary objective of this study is to evaluate the Injection Related Erythema (IRE) mitigation effect of a single administration of brimonidine tartrate in comparison with a vehicle gel (placebo). The secondary study objectives are to evaluate the IRE mitigation effect of a single administration of brimonidine tartrate in comparison with a vehicle gel on a more stringent definition scale, in accordance with the primary endpoint of the original brimonidine pivotal trials and participants' satisfaction with the overall appearance of their skin.
NCT02616250 ↗ MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea. Completed Galderma Phase 4 2015-12-01 The main objective of this study is to evaluate the efficacy of Ivermectin 1% cream (IVM) associated with Brimonidine 0.33% gel (Br) compared with the association of their respective vehicles in the treatment of moderate to severe rosacea.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Mirvaso

Condition Name

Condition Name for Mirvaso
Intervention Trials
Rosacea 5
Alcohol-Related Disorders 1
Aldehyde Dehydrogenase Deficiency 1
Chronic Persistent Vascular Facial Erythema 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Mirvaso
Intervention Trials
Rosacea 6
Erythema 4
Flushing 2
Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Mirvaso

Trials by Country

Trials by Country for Mirvaso
Location Trials
United States 30
Brazil 3
Canada 2
Denmark 1
Germany 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Mirvaso
Location Trials
California 4
North Carolina 4
Florida 3
Arkansas 3
Texas 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Mirvaso

Clinical Trial Phase

Clinical Trial Phase for Mirvaso
Clinical Trial Phase Trials
Phase 4 8
Phase 3 1
Phase 2 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Mirvaso
Clinical Trial Phase Trials
Completed 9
Terminated 2
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Mirvaso

Sponsor Name

Sponsor Name for Mirvaso
Sponsor Trials
Wake Forest University Health Sciences 3
Galderma 2
Galderma R&D 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Mirvaso
Sponsor Trials
Industry 10
Other 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
McKinsey
AstraZeneca
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.